ARTEMIS highlights VEGF inhibitors as effective partners for EGFR TKIs in EGFR mutant NSCLC.
- Resource Type
- Article
- Authors
- Le, Xiuning; Nilsson, Monique B.; Robichaux, Jacqulyne P.; Heymach, John V.
- Source
- Cancer Cell. Sep2021, Vol. 39 Issue 9, p1178-1180. 3p.
- Subject
- *BEVACIZUMAB
*EPIDERMAL growth factor receptors
*VASCULAR endothelial growth factor antagonists
*NON-small-cell lung carcinoma
*PROGRESSION-free survival
- Language
- ISSN
- 1535-6108
The randomized ARTEMIS study demonstrates that adding the VEGF inhibitor bevacizumab to the EGFR inhibitor erlotinib improves progression-free survival in EGFR mutant non-small-cell lung cancer by more than 6 months, with even greater benefits seen in patients with brain metastases and EGFR L858R mutation. This provides further evidence for the tailored use of VEGF/EGFR combinations. [ABSTRACT FROM AUTHOR]